Skip to main content
. 2022 Jul 8;13:3955. doi: 10.1038/s41467-022-31645-1

Fig. 2. Inhibiting PRMT5 methyltransferase activity attenuates primary tumor growth and metastasis.

Fig. 2

a Schematic diagram of PRMT5 inhibitor GSK3326595 (GSK595) in vivo study in the kidney renal capsule implantation xenograft model. b Tumor mass of CHLA20 iRFP720-Luc xenograft tumors from mice treated with vehicle (n = 9) or GSK595 (n = 10) (top) and representative in vivo bioluminescent images and quantification of tumor (bottom). Tumor mass was calculated by subtracting the weight of the normal kidney from the weight of the kidney that was implanted with tumor cells. Representative ex vivo images of the tumor by light microscope (c) or bioluminescence (d). e Tumor mass of NGP iRFP720-Luc xenograft tumors from mice treated with vehicle (n = 7) or GSK595 (n = 9) (top) and representative in vivo bioluminescent images and quantification of tumor (bottom). Representative ex vivo images of the tumor by light microscope (f) or bioluminescence (g). h Representative ex vivo bioluminescent images of liver from mice bearing CHLA 20 or NGP xenograft tumors treated with vehicle or GSK595. i Representative charts of FACS analysis of iRFP720 positive human neuroblastoma cells in hepatocytes isolated from the whole liver from CHLA20 xenografted mice, NC negative control. j Quantification of the percentage of iRFP720 positive tumor cells determined by flow cytometry in hepatocytes isolated from the whole liver from CHLA20 xenografted mice. Vehicle, n = 9, GSK595, n = 7, NC, n = 4. p values were indicated by a two-tailed unpaired Student’s t-test using Microsoft Excel; error bars represent SD (b, e, j).